CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
gp100 +2 moredrug
Likely dose
gp100 1 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00960752
NCT00960752Phase 2Completed
CompareCT.gov

Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

M.D. Anderson Cancer Center·interventional·Posted Aug 18, 2009·Updated Aug 13, 2021

In Brief

A Phase 2 clinical trial evaluating gp100, R848 gel, and 1 other intervention for Melanoma. Completed, enrolled 47 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune system against melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 18, 2009
Enrollment StartMay 20, 2010
Primary CompletionJul 20, 2020
TodayJul 2, 2026
Enrollment to primary: 10.2 yearsPosted 16.9 years ago

Interventions

gp100drug

1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.

R848 geldrug

Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.

MAGE-3drug

1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.